HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 12, 2020

Primary Completion Date

April 28, 2023

Study Completion Date

April 28, 2023

Conditions
Diabetic Retinopathy
Interventions
DRUG

BI 764524

BI 764524

DRUG

Sham control of BI 764524

Sham control of BI 764524

Trial Locations (19)

10003

New York Eye and Ear Infirmary of Mount Sinai, New York

11021

Long Island Vitreoretinal Consultants, Great Neck

32806

Florida Retina Institute, Orlando

36301

Trinity Research, Dothan

44195

Cleveland Clinic, Cleveland

46290

Raj K. Maturi, MD PC, Carmel

77384

Retina Consultants of Texas, The Woodlands

77401

Retina Consultants of Texas, Bellaire

78503

Valley Retina Institute, PA, McAllen

78705

Austin Research Center for Retina, PLLC, Austin

90211

Retina-Vitreous Associates Medical Group, Beverly Hills

94303

Stanford University Medical Center, Palo Alto

02115

Joslin Diabetes Center, Boston

BD9 6RJ

Bradford Royal Infirmary, Bradford

BS1 2LX

Bristol Eye Hospital, Bristol

SS0 0RY

Southend University Hospital, Essex

GL1 3NN

Gloucestershire Royal Hospital, Gloucester

EC1V 2PD

Moorfields Eye Hospital, London

SR2 9HP

Sunderland Eye Infirmary, Sunderland

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT04424290 - HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia | Biotech Hunter | Biotech Hunter